nach oben

Erschienen in:

01.12.2012

Maspin: molecular mechanisms and therapeutic implications

verfasst von: Thomas M. Bodenstine, Richard E. B. Seftor, Zhila Khalkhali-Ellis, Elisabeth A. Seftor, Philip A. Pemberton, Mary J. C. Hendrix

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2012

Einloggen, um Zugang zu erhalten

Abstract

Maspin, a non-inhibitory member of the serine protease inhibitor superfamily, has been characterized as a tumor suppressor gene in multiple cancer types. Among the established anti-tumor effects of Maspin are the inhibition of cancer cell invasion, attachment to extracellular matrices, increased sensitivity to apoptosis, and inhibition of angiogenesis. However, while significant experimental data support the role of Maspin as a tumor suppressor, clinical data regarding the prognostic implications of Maspin expression have led to conflicting results. This highlights the need for a better understanding of the context dependencies of Maspin in normal biology and how these are perturbed in the context of cancer. In this review, we outline the regulation and roles of Maspin in normal and developmental biology while discussing novel evidence and emerging theories related to its functions in cancer. We provide insight into the immense therapeutic potential of Maspin and the challenges related to its successful clinical translation.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.PubMed

Yuan, T. L., & Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27, 5497–5510.PubMed

Friedl, P., & Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 147, 992–1009.PubMed

Frese, K. K., & Tuveson, D. A. (2007). Maximizing mouse cancer models. Nature Reviews Cancer, 7, 645–658.PubMed

Jacks, T. (2005). Modeling cancer in the mouse. Harvey Lectures, 101, 1–19.PubMed

Rangarajan, A., & Weinberg, R. A. (2003). Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Reviews Cancer, 3, 952–959.PubMed

Hunter, K. (2006). Host genetics influence tumour metastasis. Nature Reviews Cancer, 6, 141–146.PubMed

Anton, K., & Glod, J. (2009). Targeting the tumor stroma in cancer therapy. Current Pharmaceutical Biotechnology, 10, 185–191.PubMed

Eccles, S. A., & Welch, D. R. (2007). Metastasis: recent discoveries and novel treatment strategies. Lancet, 369, 1742–1757.PubMed

10.

Sethi, N., & Kang, Y. (2011). Unravelling the complexity of metastasis—molecular understanding and targeted therapies. Nature Reviews Cancer, 11, 735–748.PubMed

11.

Zou, Z., Anisowicz, A., Hendrix, M. J., et al. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263, 526–529.PubMed

12.

Reddy, K. B., McGowen, R., Schuger, L., et al. (2001). Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Oncogene, 20, 6538–6543.PubMed

13.

Streuli, C. H. (2002). Maspin is a tumour suppressor that inhibits breast cancer tumour metastasis in vivo. Breast Cancer Research, 4, 137–140.PubMed

14.

Zhang, M., Shi, Y., Magit, D., et al. (2000). Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene, 19, 6053–6058.PubMed

15.

Hall, D. C., Johnson-Pais, T. L., Grubbs, B., et al. (2008). Maspin reduces prostate cancer metastasis to bone. Urologic Oncology, 26, 652–658.PubMed

16.

Watanabe, M., Nasu, Y., Kashiwakura, Y., et al. (2005). Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Human Gene Therapy, 16, 699–710.PubMed

17.

Shao, L. J., Shi, H. Y., Ayala, G., et al. (2008). Haploinsufficiency of the maspin tumor suppressor gene leads to hyperplastic lesions in prostate. Cancer Research, 68, 5143–5151.PubMed

18.

Bass, R., Fernandez, A. M., & Ellis, V. (2002). Maspin inhibits cell migration in the absence of protease inhibitory activity. Journal of Biological Chemistry, 277, 46845–46848.PubMed

19.

Ngamkitidechakul, C., Burke, J. M., O’Brien, W. J., et al. (2001). Maspin: synthesis by human cornea and regulation of in vitro stromal cell adhesion to extracellular matrix. Investigative Ophthalmology & Visual Science, 42, 3135–3141.

20.

Abraham, S., Zhang, W., Greenberg, N., et al. (2003). Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. Journal of Urology, 169, 1157–1161.PubMed

21.

Pan, Y. L., Zheng, S., Peng, J. P., et al. (2005). Effects of microencapsulated CHO cells modified with maspin gene on the motility and adhesiveness of breast carcinoma cells Bcap37. Zhonghua Zhong Liu Za Zhi, 27, 342–346.PubMed

22.

Shi, H. Y., Zhang, W., Liang, R., et al. (2001). Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Research, 61, 6945–6951.PubMed

23.

Sheng, S., Carey, J., Seftor, E. A., et al. (1996). Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 11669–11674.PubMed

24.

Jiang, N., Meng, Y., Zhang, S., et al. (2002). Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene, 21, 4089–4098.PubMed

25.

Zhang, M., Volpert, O., Shi, Y. H., et al. (2000). Maspin is an angiogenesis inhibitor. Nature Medicine, 6, 196–199.PubMed

26.

Seftor, R. E. B., Odero, V. A., Seftor, E. A., et al. (2002). Maspin suppresses breast cancer invasiveness by modulating integrin expression and function (pp. 84–95). Georgetown: Landes Bioscience, Maspin.

27.

Denk, A. E., Bettstetter, M., Wild, P. J., et al. (2007). Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Research, 20, 112–119.PubMed

28.

Law, R. H., Zhang, Q., McGowan, S., et al. (2006). An overview of the serpin superfamily. Genome Biology, 7, 216.PubMed

29.

Huntington, J. A. (2011). Serpin structure, function and dysfunction. Journal of Thrombosis and Haemostasis, 9(Suppl 1), 26–34.PubMed

30.

Hopkins, P. C., & Whisstock, J. (1994). Function of maspin. Science, 265, 1893–1894.PubMed

31.

Pemberton, P. A., Wong, D. T., Gibson, H. L., et al. (1995). The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. Journal of Biological Chemistry, 270, 15832–15837.PubMed

32.

Al-Ayyoubi, M., Gettins, P. G., & Volz, K. (2004). Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. Journal of Biological Chemistry, 279, 55540–55544.PubMed

33.

Bartuski, A. J., Kamachi, Y., Schick, C., et al. (1997). Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics, 43, 321–328.PubMed

34.

Silverman, G. A., Bartuski, A. J., Cataltepe, S., et al. (1998). SCCA1 and SCCA2 are proteinase inhibitors that map to the serpin cluster at 18q21.3. Tumor Biology, 19, 480–487.PubMed

35.

Nakashima, T., Pak, S. C., Silverman, G. A., et al. (2000). Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. Biochimica Et Biophysica Acta-Gene Structure and Expression, 1492, 441–446.

36.

Scott, F. L., Eyre, H. J., Lioumi, M., et al. (1999). Human ovalbumin serpin evolution: phylogenic analysis, gene organization, and identification of new PI8-related genes suggest that two interchromosomal and several intrachromosomal duplications generated the gene clusters at 18q21–q23 and 6p25. Genomics, 62, 490–499.PubMed

37.

Fitzpatrick, P. A., Wong, D. T., Barr, P. J., et al. (1996). Functional implications of the modeled structure of maspin. Protein Engineering, 9, 585–589.PubMed

38.

Law, R. H., Irving, J. A., Buckle, A. M., et al. (2005). The high resolution crystal structure of the human tumor suppressor maspin reveals a novel conformational switch in the G-helix. Journal of Biological Chemistry, 280, 22356–22364.PubMed

39.

Liu, T., Pemberton, P. A., & Robertson, A. D. (1999). Three-state unfolding and self-association of maspin, a tumor-suppressing serpin. Journal of Biological Chemistry, 274, 29628–29632.PubMed

40.

Umekita, Y., Hiipakka, R. A., & Liao, S. (1997). Rat and human maspins: structures, metastatic suppressor activity and mutation in prostate cancer cells. Cancer Letters, 113, 87–93.PubMed

41.

Zhang, M., Sheng, S., Maass, N., et al. (1997). mMaspin: the mouse homolog of a human tumor suppressor gene inhibits mammary tumor invasion and motility. Molecular Medicine, 3, 49–59.PubMed

42.

Sheng, S., Pemberton, P. A., & Sager, R. (1994). Production, purification, and characterization of recombinant maspin proteins. Journal of Biological Chemistry, 269, 30988–30993.PubMed

43.

Latha, K., Zhang, W., Cella, N., et al. (2005). Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition. Molecular and Cellular Biology, 25, 1737–1748.PubMed

44.

Sheng, S., Truong, B., Fredrickson, D., et al. (1998). Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proceedings of the National Academy of Sciences of the United States of America, 95, 499–504.PubMed

45.

McGowen, R., Biliran, H., Jr., Sager, R., et al. (2000). The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Research, 60, 4771–4778.PubMed

46.

Biliran, H., Jr., & Sheng, S. (2001). Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Research, 61, 8676–8682.PubMed

47.

Ngamkitidechakul, C., Warejcka, D. J., Burke, J. M., et al. (2003). Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion. Conversion of ovalbumin to a maspin-like molecule. Journal of Biological Chemistry, 278, 31796–31806.PubMed

48.

Ravenhill, L., Wagstaff, L., Edwards, D. R., et al. (2010). G-helix of maspin mediates effects on cell migration and adhesion. Journal of Biological Chemistry, 285, 36285–36292.PubMed

49.

Zhang, M., Maass, N., Magit, D., et al. (1997). Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth & Differentiation, 8, 179–186.

50.

Zhang, M., Magit, D., & Sager, R. (1997). Expression of maspin in prostate cells is regulated by a positive Ets element and a negative hormonal responsive element site recognized by androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 5673–5678.PubMed

51.

Zou, Z., Gao, C., Nagaich, A. K., et al. (2000). p53 regulates the expression of the tumor suppressor gene maspin. Journal of Biological Chemistry, 275, 6051–6054.PubMed

52.

Zhang, W., & Zhang, M. (2002). Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. International Journal of Oncology, 20, 1145–1150.PubMed

53.

Wang, S. E., Narasanna, A., Whitell, C. W., et al. (2007). Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. Journal of Biological Chemistry, 282, 5661–5669.PubMed

54.

Eitel, J. A., Bijangi-Vishehsaraei, K., Saadatzadeh, M. R., et al. (2009). PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle, 8, 896–901.PubMed

55.

Duan, H., Zhang, H. J., Yang, J. Q., et al. (2003). MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxidants & Redox Signaling, 5, 677–688.

56.

Maekawa, T., Sano, Y., Shinagawa, T., et al. (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene, 27, 1045–1054.PubMed

57.

Kim, S., Han, J., Kim, J., et al. (2004). Maspin expression is transactivated by p63 and is critical for the modulation of lung cancer progression. Cancer Research, 64, 6900–6905.PubMed

58.

Spiesbach, K., Tannapfel, A., Mossner, J., et al. (2005). TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. International Journal of Cancer, 114, 555–562.

59.

Domann, F. E., Rice, J. C., Hendrix, M. J., et al. (2000). Epigenetic silencing of maspin gene expression in human breast cancers. International Journal of Cancer, 85, 805–810.

60.

Futscher, B. W., Oshiro, M. M., Wozniak, R. J., et al. (2002). Role for DNA methylation in the control of cell type specific maspin expression. Nature Genetics, 31, 175–179.PubMed

61.

Maass, N., Biallek, M., Rosel, F., et al. (2002). Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochemical and Biophysical Research Communications, 297, 125–128.PubMed

62.

Ohike, N., Maass, N., Mundhenke, C., et al. (2003). Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Letters, 199, 193–200.PubMed

63.

Tang, B., Peng, Z. H., Yu, P. W., et al. (2006). Transcription regulation of 5-Aza-2′-deoxycytidine on maspin gene demethylation in RKO human colorectal cell line. Zhonghua Wei Chang Wai Ke Za Zhi, 9, 260–263.PubMed

64.

Murakami, J., Asaumi, J., Maki, Y., et al. (2004). Effects of demethylating agent 5-aza-2(′)-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines. Oral Oncology, 40, 597–603.PubMed

65.

Horswill, M. A., Narayan, M., Warejcka, D. J., et al. (2008). Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts. Experimental Eye Research, 86, 586–600.PubMed

66.

Fujisawa, K., Maesawa, C., Sato, R., et al. (2005). Epigenetic status and aberrant expression of the maspin gene in human hepato-biliary tract carcinomas. Laboratory Investigation, 85, 214–224.PubMed

67.

Dokras, A., Coffin, J., Field, L., et al. (2006). Epigenetic regulation of maspin expression in the human placenta. Molecular Human Reproduction, 12, 611–617.PubMed

68.

Villares, G. J., Zigler, M., Dobroff, A. S., et al. (2011). Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proceedings of the National Academy of Sciences of the United States of America, 108, 626–631.PubMed

69.

Futscher, B. W., O’Meara, M. M., Kim, C. J., et al. (2004). Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia, 6, 380–389.PubMed

70.

Boltze, C., Schneider-Stock, R., Quednow, C., et al. (2003). Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. International Journal of Molecular Medicine, 12, 479–484.PubMed

71.

Fitzgerald, M., Oshiro, M., Holtan, N., et al. (2003). Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia, 5, 427–436.PubMed

72.

Akiyama, Y., Maesawa, C., Ogasawara, S., et al. (2003). Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. American Journal of Pathology, 163, 1911–1919.PubMed

73.

Sugimoto, S., Maass, N., Takimoto, Y., et al. (2004). Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Letters, 203, 209–215.PubMed

74.

Yatabe, Y., Mitsudomi, T., & Takahashi, T. (2004). Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene, 23, 4041–4049.PubMed

75.

Wada, K., Maesawa, C., Akasaka, T., et al. (2004). Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. The Journal of Investigative Dermatology, 122, 805–811.PubMed

76.

Ogasawara, S., Maesawa, C., Yamamoto, M., et al. (2004). Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene, 23, 1117–1124.PubMed

77.

Rose, S. L., Fitzgerald, M. P., White, N. O., et al. (2006). Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecologic Oncology, 102, 319–324.PubMed

78.

Wu, Y., Alvarez, M., Slamon, D. J., et al. (2010). Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer, 10, 32.PubMed

79.

Kwon, Y. J., Lee, S. J., Koh, J. S., et al. (2012). Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. Journal of Thoracic Oncology, 7, 20–33.PubMed

80.

Beltran, A., Parikh, S., Liu, Y., et al. (2007). Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene, 26, 2791–2798.PubMed

81.

Beltran, A. S., Sun, X., Lizardi, P. M., et al. (2008). Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Molecular Cancer Therapeutics, 7, 1080–1090.PubMed

82.

Beltran, A. S., & Blancafort, P. (2011). Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics, 6, 224–235.PubMed

83.

Khalkhali-Ellis, Z., & Hendrix, M. J. (2003). Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. American Journal of Pathology, 162, 1411–1417.PubMed

84.

Girish, G. V., Bhattacharya, G., & Sinha, A. K. (2006). The role of insulin dependent NO synthesis in the impaired production of maspin in human breast cancer. Journal of Cancer Research and Clinical Oncology, 132, 389–398.PubMed

85.

Girish, G. V., Sinha, N., Chakraborty, K., et al. (2006). Restoration by aspirin of impaired plasma maspin level in human breast cancer. Acta Oncologica, 45, 184–187.PubMed

86.

Bhattacharyya, M., Girish, G. V., Ghosh, R., et al. (2010). Acetyl salicylic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients [corrected]. Cancer Science, 101, 2105–2109.PubMed

87.

Lim, S., Hung, A. C., & Porter, A. G. (2009). Focused PCR screen reveals p53 dependence of nitric oxide-induced apoptosis and up-regulation of maspin and plasminogen activator inhibitor-1 in tumor cells. Molecular Cancer Research, 7, 55–66.PubMed

88.

Shao, Z. M., Radziszewski, W. J., & Barsky, S. H. (2000). Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Letters, 157, 133–144.PubMed

89.

Khalkhali-Ellis, Z., Christian, A. L., Kirschmann, D. A., et al. (2004). Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clinical Cancer Research, 10, 449–454.PubMed

90.

Liu, Z., Shi, H. Y., Nawaz, Z., et al. (2004). Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Cancer Letters, 209, 55–65.PubMed

91.

Jiang, W. G., Hiscox, S., Horrobin, D. F., et al. (1997). Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochemical and Biophysical Research Communications, 237, 639–644.PubMed

92.

Mueller, E., Sarraf, P., Tontonoz, P., et al. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell, 1, 465–470.PubMed

93.

Teoh, S. S., Whisstock, J. C., & Bird, P. I. (2010). Maspin (SERPINB5) is an obligate intracellular serpin. Journal of Biological Chemistry, 285, 10862–10869.PubMed

94.

Odero-Marah, V. A., Khalkhali-Ellis, Z., Schneider, G. B., et al. (2002). Tyrosine phosphorylation of maspin in normal mammary epithelia and breast cancer cells. Biochemical and Biophysical Research Communications, 295, 800–805.PubMed

95.

Narayan, M., Mirza, S. P., & Twining, S. S. (2011). Identification of phosphorylation sites on extracellular corneal epithelial cell maspin. Proteomics, 11, 1382–1390.PubMed

96.

Nawata, S., Shi, H. Y., Sugino, N., et al. (2011). Evidence of post-translational modification of the tumor suppressor maspin under oxidative stress. International Journal of Molecular Medicine, 27, 249–254.PubMed

97.

Zhang, M., Magit, D., Botteri, F., et al. (1999). Maspin plays an important role in mammary gland development. Developmental Biology, 215, 278–287.PubMed

98.

Bailey, C. M., Khalkhali-Ellis, Z., Kondo, S., et al. (2005). Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. Journal of Biological Chemistry, 280, 34210–34217.PubMed

99.

Bailey, C. M., Abbott, D. E., Margaryan, N. V., et al. (2008). Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Molecular and Cellular Biology, 28, 2235–2243.PubMed

100.

Bailey, C. M., Margaryan, N. V., Abbott, D. E., et al. (2009). Temporal and spatial expression patterns for the tumor suppressor Maspin and its binding partner interferon regulatory factor 6 during breast development. Development, Growth & Differentiation, 51, 473–481.

101.

Gao, F., Shi, H. Y., Daughty, C., et al. (2004). Maspin plays an essential role in early embryonic development. Development, 131, 1479–1489.PubMed

102.

Dokras, A., Gardner, L. M., Kirschmann, D. A., et al. (2002). The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta, 23, 274–280.PubMed

103.

Chim, S. S., Tong, Y. K., Chiu, R. W., et al. (2005). Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America, 102, 14753–14758.PubMed

104.

Pemberton, P. A., Tipton, A. R., Pavloff, N., et al. (1997). Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. Journal of Histochemistry and Cytochemistry, 45, 1697–1706.PubMed

105.

Katz, A. B., & Taichman, L. B. (1999). A partial catalog of proteins secreted by epidermal keratinocytes in culture. Journal of Investigative Dermatology, 112, 818–821.PubMed

106.

Qin, L., & Zhang, M. (2010). Maspin regulates endothelial cell adhesion and migration through an integrin signaling pathway. Journal of Biological Chemistry, 285, 32360–32369.PubMed

107.

Endsley, M. P., Hu, Y., Deng, Y., et al. (2011). Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion. Journal of Biological Chemistry, 286, 24599–24607.PubMed

108.

Toillon, R. A., Lagadec, C., Page, A., et al. (2007). Proteomics demonstration that normal breast epithelial cells can induce apoptosis of breast cancer cells through insulin-like growth factor-binding protein-3 and maspin. Molecular & Cellular Proteomics, 6, 1239–1247.

109.

Khalkhali-Ellis, Z., & Hendrix, M. J. (2007). Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Research, 67, 3535–3539.PubMed

110.

Yu, X., Harris, S. L., & Levine, A. J. (2006). The regulation of exosome secretion: a novel function of the p53 protein. Cancer Research, 66, 4795–4801.PubMed

111.

Hojo, T., Akiyama, Y., Nagasaki, K., et al. (2001). Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Letters, 171, 103–110.PubMed

112.

Sopel, M., Kasprzyk, I., & Berdowska, I. (2005). Maspin and c-erbB-2 expression in correlation with microvessel density in invasive ductal breast cancer. Folia Histochemica et Cytobiologica, 43, 109–116.PubMed

113.

Sharma, G., Mirza, S., Parshad, R., et al. (2011). Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biology, 32, 23–32.PubMed

114.

Maass, N., Teffner, M., Rosel, F., et al. (2001). Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. The Journal of Pathology, 195, 321–326.PubMed

115.

Maass, N., Hojo, T., Rosel, F., et al. (2001). Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clinical Biochemistry, 34, 303–307.PubMed

116.

Machtens, S., Kuczyk, M., Serth, J., et al. (2000). P53 regulated maspin protein expression determines recurrence-free survival of patients with localised prostate cancer. Prostate Cancer and Prostatic Diseases, 3, S27.PubMed

117.

Maass, N., Nagasaki, K., Ziebart, M., et al. (2002). Expression and regulation of tumor suppressor gene maspin in breast cancer. Clinical Breast Cancer, 3, 281–287.PubMed

118.

Stark, A. M., Schem, C., Maass, N., et al. (2010). Expression of metastasis suppressor gene maspin is reduced in breast cancer brain metastases and correlates with the estrogen receptor status. Neurological Research, 32, 303–308.PubMed

119.

Umekita, Y., Ohi, Y., Sagara, Y., et al. (2002). Expression of maspin predicts poor prognosis in breast-cancer patients. International Journal of Cancer, 100, 452–455.

120.

Bieche, I., Girault, I., Sabourin, J. C., et al. (2003). Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. British Journal of Cancer, 88, 863–870.PubMed

121.

Joensuu, K. M., Leidenius, M. H., Andersson, L. C., et al. (2009). High expression of maspin is associated with early tumor relapse in breast cancer. Human Pathology, 40, 1143–1151.PubMed

122.

Umekita, Y., & Yoshida, H. (2003). Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology, 42, 541–545.PubMed

123.

Lee, M. J., Suh, C. H., & Li, Z. H. (2006). Clinicopathological significance of maspin expression in breast cancer. Journal of Korean Medical Science, 21, 309–314.PubMed

124.

Tsoli, E., Tsantoulis, P. K., Papalambros, A., et al. (2007). Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer. Journal of Clinical Pathology, 60, 261–266.PubMed

125.

Kim, D. H., Yoon, D. S., Dooley, W. C., et al. (2003). Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer. Histopathology, 42, 37–42.PubMed

126.

Boltze, C., Schneider-Stock, R., Meyer, F., et al. (2003). Maspin in thyroid cancer: its relationship with p53 and clinical outcome. Oncology Reports, 10, 1783–1787.PubMed

127.

Ito, Y., Yoshida, H., Tomoda, C., et al. (2004). Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. Thyroid, 14, 13–18.PubMed

128.

Boltze, C., Hoang-Vu, C., Schneider-Stock, R., et al. (2004). Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis. Verhandlungen der Deutschen Gesellschaft für Pathologie, 88, 237–245.PubMed

129.

Son, H. J., Sohn, T. S., Song, S. Y., et al. (2002). Maspin expression in human gastric adenocarcinoma. Pathology International, 52, 508–513.PubMed

130.

Wang, M. C., Yang, Y. M., Li, X. H., et al. (2004). Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. World Journal of Gastroenterology, 10, 634–637.PubMed

131.

Zheng, H. C., Wang, M. C., Li, J. Y., et al. (2004). Expression of maspin and kai1 and their clinicopathological significance in carcinogenesis and progression of gastric cancer. Chinese Medical Sciences Journal, 19, 193–198.PubMed

132.

Kim, S. M., Cho, S. J., Jang, W. Y., et al. (2005). Expression of maspin is associated with the intestinal type of gastric adenocarcinoma. Cancer Research and Treatment, 37, 228–232.PubMed

133.

Song, S. Y., Son, H. J., Kim, M. H., et al. (2007). Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepato-Gastroenterology, 54, 973–976.PubMed

134.

Ito, R., Nakayama, H., Yoshida, K., et al. (2004). Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncology Reports, 12, 985–990.PubMed

135.

Terashima, M., Maesawa, C., Oyama, K., et al. (2005). Gene expression profiles in human gastric cancer: expression of maspin correlates with lymph node metastasis. British Journal of Cancer, 92, 1130–1136.PubMed

136.

Yu, M., Zheng, H., Tsuneyama, K., et al. (2007). Paradoxical expression of maspin in gastric carcinomas: correlation with carcinogenesis and progression. Human Pathology, 38, 1248–1255.PubMed

137.

He, Y., Zhang, L., Li, Y. J., et al. (2007). Expression of maspin protein and correlation between maspin and P53 proteins in gastric carcinoma. Zhonghua Yi Xue Za Zhi, 87, 909–912.PubMed

138.

Lee, D. Y., Park, C. S., Kim, H. S., et al. (2008). Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Applied Immunohistochemistry & Molecular Morphology, 16, 13–18.

139.

Boltze, C. (2005). Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathology Research and Practice, 200, 783–790.

140.

Zheng, H., Tsuneyama, K., Cheng, C., et al. (2007). Maspin expression was involved in colorectal adenoma–adenocarcinoma sequence and liver metastasis of tumors. Anticancer Research, 27, 259–265.PubMed

141.

Markl, B., Arnholdt, H. M., Jahnig, H., et al. (2010). Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. Human Pathology, 41, 1024–1033.PubMed

142.

Song, S. Y., Lee, S. K., Kim, D. H., et al. (2002). Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Digestive Diseases and Sciences, 47, 1831–1835.PubMed

143.

Fung, C. L., Chan, C., Jankova, L., et al. (2010). Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology, 56, 319–330.PubMed

144.

Xia, W., Lau, Y. K., Hu, M. C., et al. (2000). High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. Oncogene, 19, 2398–2403.PubMed

145.

Yasumatsu, R., Nakashima, T., Hirakawa, N., et al. (2001). Maspin expression in stage I and II oral tongue squamous cell carcinoma. Head & Neck, 23, 962–966.

146.

Nakashima, M., Ohike, N., Nagasaki, K., et al. (2004). Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 130, 475–479.PubMed

147.

Li, H. W., Leung, S. W., Cheung, A. N., et al. (2006). Expression of maspin in gestational trophoblastic disease. Gynecologic Oncology, 101, 76–81.PubMed

148.

Vereecken, P., Reynaert, S., Lalmand, M. C., et al. (2006). Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions. The Journal of International Medical Research, 34, 52–57.PubMed

149.

Surowiak, P., Materna, V., Drag-Zalesinska, M., et al. (2006). Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. International Journal of Gynecological Pathology, 25, 131–139.PubMed

150.

Beecken, W. D., Engl, T., Engels, K., et al. (2006). Clinical relevance of maspin expression in bladder cancer. World Journal of Urology, 24, 338–344.PubMed

151.

Blandamura, S., Giacomelli, L., Leo, G., et al. (2006). Nuclear maspin detection in renal cell tumours: possible diagnostic role and correlation with p53 status. Histopathology, 49, 274–282.PubMed

152.

Nakagawa, M., Katakura, H., Adachi, M., et al. (2006). Maspin expression and its clinical significance in non-small cell lung cancer. Annals of Surgical Oncology, 13, 1517–1523.PubMed

153.

Romani, A. A., Soliani, P., Desenzani, S., et al. (2006). The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer, 6, 255.PubMed

154.

Iezzi, G., Piattelli, A., Rubini, C., et al. (2007). Maspin expression in oral squamous cell carcinoma. The Journal of Craniofacial Surgery, 18, 1039–1043.PubMed

155.

Schwarz, S., Ettl, T., Kleinsasser, N., et al. (2008). Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncology, 44, 563–570.PubMed

156.

Kashima, K., Ohike, N., Mukai, S., et al. (2008). Expression of the tumor suppressor gene maspin and its significance in intraductal papillary mucinous neoplasms of the pancreas. Hepatobiliary & Pancreatic Diseases International, 7, 86–90.

157.

Marioni, G., Koussis, H., Gaio, E., et al. (2009). MASPIN’s prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence. Acta Oto-Laryngologica, 129, 786–792.PubMed

158.

Takanami, I., Abiko, T., & Koizumi, S. (2008). Expression of maspin in non-small-cell lung cancer: correlation with clinical features. Clinical Lung Cancer, 9, 361–366.PubMed

159.

Klasa-Mazurkiewicz, D., Narkiewicz, J., Milczek, T., et al. (2009). Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients. Gynecologic Oncology, 113, 91–98.PubMed

160.

Chua, R., Setzer, S., Govindarajan, B., et al. (2009). Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. Journal of the American Academy of Dermatology, 60, 758–766.PubMed

161.

Ma, Y., & Peng, Z. L. (2009). Expression of maspin and its relation to tumor vascularization in epithelian ovarian cancer. Sichuan Da Xue Xue Bao. Yi Xue Ban, 40, 223–227.PubMed

162.

Yoshizawa, K., Nozaki, S., Okamune, A., et al. (2009). Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. Journal of Oral Pathology & Medicine, 38, 535–539.

163.

Marioni, G., Staffieri, A., Bertolin, A., et al. (2010). Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. European Archives of Oto-Rhino-Laryngology, 267, 1103–1110.PubMed

164.

Marioni, G., Koussis, H., Scola, A., et al. (2010). Expression of MASPIN and angiogenin in nasopharyngeal carcinoma: novel preliminary clinico-pathological evidence. Acta Oto-Laryngologica, 130, 952–958.PubMed

165.

Adim, S. B., Filiz, G., Kanat, O., et al. (2010). Maspin expression in gastrointestinal stromal tumors. World Journal of Surgical Oncology, 8, 22.PubMed

166.

Yoshizawa, K., Nozaki, S., Kitahara, H., et al. (2011). Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: association with mode of invasion and clinicopathological factors. Oncology Reports, 26, 1555–1560.PubMed

167.

Ghazy, S. E., Helmy, I. M., & Baghdadi, H. M. (2011). Maspin and MCM2 immunoprofiling in salivary gland carcinomas. Diagnostic Pathology, 6, 89.PubMed

168.

Smith, S. L., Watson, S. G., Ratschiller, D., et al. (2003). Maspin—the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer—is strongly expressed in preneoplastic bronchial lesions. Oncogene, 22, 8677–8687.PubMed

169.

Xu, C., Quddus, M. R., Sung, C. J., et al. (2005). Maspin expression in CIN 3, microinvasive squamous cell carcinoma, and invasive squamous cell carcinoma of the uterine cervix. Modern Pathology, 18, 1102–1106.PubMed

170.

Nakashima, D., Uzawa, K., Kasamatsu, A., et al. (2006). Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. International Journal of Cancer, 118, 704–713.

171.

Cao, D., Wilentz, R. E., Abbruzzese, J. L., et al. (2005). Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. International Journal of Gastrointestinal Cancer, 36, 39–46.PubMed

172.

Maesawa, C., Ogasawara, S., Yashima-Abo, A., et al. (2006). Aberrant maspin expression in gallbladder epithelium is associated with intestinal metaplasia in patients with cholelithiasis. Journal of Clinical Pathology, 59, 328–330.PubMed

173.

Abd El-Wahed, M. M. (2005). Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. Journal of the Egyptian National Cancer Institute, 17, 173–183.PubMed

174.

Cao, D., Zhang, Q., Wu, L. S., et al. (2007). Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Modern Pathology, 20, 570–578.PubMed

175.

Nash, J. W., Bhardwaj, A., Wen, P., et al. (2007). Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Applied Immunohistochemistry & Molecular Morphology, 15, 59–63.

176.

Wang, D. L., Wang, Y. F., Shi, G. S., et al. (2007). Correlation of hTERT expression to maspin and bFGF expression and their significance in glioma. Ai Zheng, 26, 601–606.PubMed

177.

Shams, T. M., Samaka, R. M., & Shams, M. E. (2006). Maspin protein expression: a special feature of papillary thyroid carcinoma. Journal of the Egyptian National Cancer Institute, 18, 274–280.PubMed

178.

Tsuji, T., Umekita, Y., Ohi, Y., et al. (2007). Maspin expression is up-regulated during the progression of endometrioid endometrial carcinoma. Histopathology, 51, 871–874.PubMed

179.

Sood, A. K., Fletcher, M. S., Gruman, L. M., et al. (2002). The paradoxical expression of maspin in ovarian carcinoma. Clinical Cancer Research, 8, 2924–2932.PubMed

180.

Secord, A. A., Lee, P. S., Darcy, K. M., et al. (2006). Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecologic Oncology, 101, 390–397.PubMed

181.

Li, H. W., Leung, S. W., Chan, C. S., et al. (2007). Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncology Reports, 17, 393–398.PubMed

182.

Shui, H. H., Luo, L., Liang, S. Z., et al. (2008). The expression of Maspin protein in oral squamous cell carcinoma and its significance. Hua Xi Kou Qiang Yi Xue Za Zhi, 26(604–6), 610.

183.

Kim, J., Jang, K. T., Kim, K. H., et al. (2010). Aberrant maspin expression is involved in early carcinogenesis of gallbladder cancer. Tumour Biology, 31, 471–476.PubMed

184.

Bauerschlag, D. O., Habermann, M., Weimer, J., et al. (2010). Heterogeneous expression of serine protease inhibitor maspin in ovarian cancer. Anticancer Research, 30, 2739–2744.PubMed

185.

Umekita, Y., Ohi, Y., Souda, M., et al. (2011). Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer. Diagnostic Pathology, 6, 36.PubMed

186.

Bal, N., Kocer, N. E., Ertorer, M. E., et al. (2008). Maspin, E-selectin, and P-selectin expressions in papillary thyroid carcinomas and their correlation with prognostic parameters. Pathology Research and Practice, 204, 743–750.

187.

Woenckhaus, M., Bubendorf, L., Dalquen, P., et al. (2007). Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. Journal of Clinical Pathology, 60, 483–486.PubMed

188.

Webber, B. A., Lawson, D., & Cohen, C. (2008). Maspin and Mutant p53 expression in malignant melanoma and carcinoma: use of tissue microarray. Applied Immunohistochemistry & Molecular Morphology, 16, 19–23.

189.

Cho, J. H., Kim, H. S., Park, C. S., et al. (2007). Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncology, 43, 272–277.PubMed

190.

Goulet, B., Chan, G., Chambers, A. F., et al. (2011). An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochemistry and Cell Biology, 90, 22–38.PubMed

191.

Mohsin, S. K., Zhang, M., Clark, G. M., et al. (2003). Maspin expression in invasive breast cancer: association with other prognostic factors. The Journal of Pathology, 199, 432–435.PubMed

192.

Goulet, B., Kennette, W., Ablack, A., et al. (2011). Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Laboratory Investigation, 91, 1181–1187.PubMed

193.

Marioni, G., Blandamura, S., Giacomelli, L., et al. (2005). Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology, 46, 576–582.PubMed

194.

Marioni, G., D’Alessandro, E., Giacomelli, L., et al. (2006). Maspin nuclear localization is related to reduced density of tumour-associated micro-vessels in laryngeal carcinoma. Anticancer Research, 26, 4927–4932.PubMed

195.

Solomon, L. A., Munkarah, A. R., Schimp, V. L., et al. (2006). Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecologic Oncology, 101, 385–389.PubMed

196.

Sopel, M., Surowiak, P., & Berdowska, I. (2010). Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma. Folia Morphologica (Warsz), 69, 204–212.

197.

Lonardo, F., Li, X. H., Siddiq, F., et al. (2006). Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer, 51, 31–39.PubMed

198.

Marioni, G., Giacomelli, L., D’Alessandro, E., et al. (2008). Nuclear localization of mammary serine protease inhibitor (MASPIN): is its impact on the prognosis in laryngeal carcinoma due to a proapoptotic effect? American Journal of Otolaryngology, 29, 156–162.PubMed

199.

Marioni, G., Staffieri, C., Staffieri, A., et al. (2009). MASPIN tumour-suppressing activity in head and neck squamous cell carcinoma: emerging evidence and therapeutic perspectives. Acta Oto-Laryngologica, 129, 476–480.PubMed

200.

Frey, A., Soubani, A. O., Adam, A. K., et al. (2009). Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in stage I, improved survival. Histopathology, 54, 590–597.PubMed

201.

Marioni, G., Blandamura, S., Lionello, M., et al. (2011). Nuclear MASPIN expression relates to a better prognosis in elderly patients with laryngeal carcinoma. Acta Oto-Laryngologica, 131, 1220–1225.PubMed

202.

Blandamura, S., D’Alessandro, E., Giacomelli, L., et al. (2008). Expression of maspin in papillary Ta/T1 bladder neoplasms. Anticancer Research, 28, 471–478.PubMed

203.

Zheng, H. C., Saito, H., Masuda, S., et al. (2008). Cytoplasmic and nuclear maspin expression in lung carcinomas: an immunohistochemical study using tissue microarrays. Applied Immunohistochemistry & Molecular Morphology, 16, 459–465.

204.

Bettstetter, M., Woenckhaus, M., Wild, P. J., et al. (2005). Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. The Journal of Pathology, 205, 606–614.PubMed

205.

Dietmaier, W., Bettstetter, M., Wild, P. J., et al. (2006). Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. International Journal of Cancer, 118, 2247–2254.

206.

Jang, H. L., Nam, E., Lee, K. H., et al. (2008). Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. International Journal of Molecular Medicine, 22, 333–338.PubMed

207.

Yeom, S. Y., Jang, H. L., Lee, S. J., et al. (2010). Interaction of testisin with maspin and its impact on invasion and cell death resistance of cervical cancer cells. FEBS Letters, 584, 1469–1475.PubMed

208.

Chambers, A. F. (2009). MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Research, 69, 5292–5293.PubMed

209.

Cai, Z., Zhou, Y., Lei, T., et al. (2009). Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial–mesenchymal transition of esophageal carcinoma cells. Cancer, 115, 36–48.PubMed

210.

Shi, H. Y., Stafford, L. J., Liu, Z., et al. (2007). Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase. Cell Motility and the Cytoskeleton, 64, 338–346.PubMed

211.

Reis-Filho, J. S., Milanezi, F., Silva, P., et al. (2001). Maspin expression in myoepithelial tumors of the breast. Pathology Research and Practice, 197, 817–821.

212.

Lele, S. M., Graves, K., & Gatalica, Z. (2000). Immunohistochemical detection of maspin is a useful adjunct in distinguishing radial sclerosing lesion from tubular carcinoma of the breast. Applied Immunohistochemistry & Molecular Morphology, 8, 32–36.

213.

Sternlicht, M. D., & Barsky, S. H. (1997). The myoepithelial defense: a host defense against cancer. Medical Hypotheses, 48, 37–46.PubMed

214.

Sternlicht, M. D., Kedeshian, P., Shao, Z. M., et al. (1997). The human myoepithelial cell is a natural tumor suppressor. Clinical Cancer Research, 3, 1949–1958.PubMed

215.

Shao, Z. M., Nguyen, M., Alpaugh, M. L., et al. (1998). The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21(WAF1/CIP1) induction, G(2)/M arrest, and apoptosis. Experimental Cell Research, 241, 394–403.PubMed

216.

Shao, Z., & Shen, Z. (1999). Human breast myoepithelial cell blocks estrogen receptor-negative breast carcinoma cell invasion. Zhonghua Yi Xue Za Zhi, 79, 214–216.PubMed

217.

Martins, M. T., Altemani, A., Freitas, L., et al. (2005). Maspin expression in carcinoma ex pleomorphic adenoma. Journal of Clinical Pathology, 58, 1311–1314.PubMed

218.

Campbell, I. D. & Humphries, M. J. (2011). Integrin structure, activation, and interactions. Cold Spring Harbor Perspectives in Biology, 3, a004994.

219.

Seftor, R. E., Seftor, E. A., & Hendrix, M. J. (1999). Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Reviews, 18, 359–375.PubMed

220.

Seftor, R. E., Seftor, E. A., Sheng, S., et al. (1998). maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Research, 58, 5681–5685.PubMed

221.

Cella, N., Contreras, A., Latha, K., et al. (2006). Maspin is physically associated with [beta]1 integrin regulating cell adhesion in mammary epithelial cells. The FASEB Journal, 20, 1510–1512.

222.

Bass, R., Wagstaff, L., Ravenhill, L., et al. (2009). Binding of extracellular maspin to beta1 integrins inhibits vascular smooth muscle cell migration. Journal of Biological Chemistry, 284, 27712–27720.PubMed

223.

Tahmatzopoulos, A., Sheng, S., & Kyprianou, N. (2005). Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene, 24, 5375–5383.PubMed

224.

Li, X., Chen, D., Yin, S., et al. (2007). Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. Journal of Cellular Physiology, 212, 298–306.PubMed

225.

Liu, J., Yin, S., Reddy, N., et al. (2004). Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Research, 64, 1703–1711.PubMed

226.

Zhang, W., Shi, H. Y., & Zhang, M. (2005). Maspin overexpression modulates tumor cell apoptosis through the regulation of Bcl-2 family proteins. BMC Cancer, 5, 50.PubMed

227.

Zheng, A. H., Yi, Y. F., & Zhou, W. W. (2008). Construction of a eukaryotic vector expressing MASPIN gene and its effect on cell apoptosis in gastric cancer cell line SGC7901. Ai Zheng, 27, 1161–1165.PubMed

228.

Lee, S. J., Jang, H., & Park, C. (2012). Maspin increases Ku70 acetylation and Bax-mediated cell death in cancer. International Journal of Molecular Medicine, 29, 225–230.PubMed

229.

Blandamura, S., D’Alessandro, E., Guzzardo, V., et al. (2007). Maspin expression in adenocarcinoma of the ampulla of Vater: relation with clinicopathological parameters and apoptosis. Anticancer Research, 27, 1059–1065.PubMed

230.

Payne, C. M., Holubec, H., Crowley-Skillicorn, C., et al. (2011). Maspin is a deoxycholate-inducible, anti-apoptotic stress-response protein differentially expressed during colon carcinogenesis. Clinical and Experimental Gastroenterology, 4, 239–253.PubMed

231.

Cher, M. L., Biliran, H. R., Jr., Bhagat, S., et al. (2003). Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100, 7847–7852.PubMed

232.

Nickoloff, B. J., Lingen, M. W., Chang, B. D., et al. (2004). Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Research, 64, 2956–2961.PubMed

233.

Friedrich, M. G., Toma, M. I., Petri, S., et al. (2004). Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. European Urology, 45, 737–743.PubMed

234.

Bolat, F., Gumurdulu, D., Erkanli, S., et al. (2008). Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathology Research and Practice, 204, 379–387.

235.

Li, Z., Shi, H. Y., & Zhang, M. (2005). Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene, 24, 2008–2019.PubMed

236.

Bailey, C. M., Khalkhali-Ellis, Z., Seftor, E. A., et al. (2006). Biological functions of maspin. Journal of Cellular Physiology, 209, 617–624.PubMed

237.

Yin, S., Li, X., Meng, Y., et al. (2005). Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. Journal of Biological Chemistry, 280, 34985–34996.PubMed

238.

Li, X., Yin, S., Meng, Y., et al. (2006). Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Research, 66, 9323–9329.PubMed

239.

Lei, K. F., Liu, B. Y., Wang, Y. F., et al. (2011). SerpinB5 interacts with KHDRBS3 and FBXO32 in gastric cancer cells. Oncology Reports, 26, 1115–1120.PubMed

240.

Lei, K. F., Wang, Y. F., Wang, Q. Q., et al. (2012). Interaction of SerpinB5 and MAFbx in gastric cancer cell and its action site. Zhonghua Wei Chang Wai Ke Za Zhi, 15, 169–173.PubMed

241.

Staunton, J. E., Slonim, D. K., Coller, H. A., et al. (2001). Chemosensitivity prediction by transcriptional profiling. Proceedings of the National Academy of Sciences of the United States of America, 98, 10787–10792.PubMed

242.

Nakatsu, N., Yoshida, Y., Yamazaki, K., et al. (2005). Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Molecular Cancer Therapeutics, 4, 399–412.PubMed

243.

Salter, K. H., Acharya, C. R., Walters, K. S., et al. (2008). An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One, 3, e1908.PubMed

244.

Nam, E., & Park, C. (2010). Maspin suppresses survival of lung cancer cells through modulation of Akt pathway. Cancer Research and Treatment, 42, 42–47.PubMed

245.

Ben Shachar, B., Feldstein, O., Hacohen, D., et al. (2010). The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Molecular Cancer Research, 8, 363–372.PubMed

246.

Khalkhali-Ellis, Z., Abbott, D. E., Bailey, C. M., et al. (2008). IFN-gamma regulation of vacuolar pH, cathepsin D processing and autophagy in mammary epithelial cells. Journal of Cellular Biochemistry, 105, 208–218.PubMed

247.

Khalkhali-Ellis, Z. (2006). Maspin: the new frontier. Clinical Cancer Research, 12, 7279–7283.PubMed

248.

Capony, F., Rougeot, C., Montcourrier, P., et al. (1989). Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Research, 49, 3904–3909.PubMed

249.

Vignon, F., Capony, F., Chambon, M., et al. (1986). Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology, 118, 1537–1545.PubMed

250.

Harvat, B. L., & Jetten, A. M. (1996). Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth & Differentiation, 7, 289–300.

251.

Narayan, M., & Twining, S. (2010). Focus on molecules: maspin. Experimental Eye Research, 90, 2–3.

Titel: Maspin: molecular mechanisms and therapeutic implications
verfasst von: Thomas M. Bodenstine
Richard E. B. Seftor
Zhila Khalkhali-Ellis
Elisabeth A. Seftor
Philip A. Pemberton
Mary J. C. Hendrix
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3-4/2012
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-012-9361-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Maspin: molecular mechanisms and therapeutic implications

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3-4/2012

Non-glucose metabolism in cancer cells—is it all in the fat?

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies

MicroRNA control of epithelial–mesenchymal transition and metastasis

Raf kinase inhibitor protein (RKIP) in cancer

Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment

Preface

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie